Children with CKD, ACEi versus standard treatment contents www.kidney-international.org KDIGO EXECUTIVE COMMITTEE Garabed Eknoyan, MD Norbert Lameire, MD, PhD Founding KDIGO Co-Chairs David C. Wheeler, MD, FRCP Immediate Past Co-Chair Michel Jadoul, MD KDIGO Co-Chair Wolfgang C. Winkelmayer, MD, MPH, ScD KDIGO Co-Chair Mustafa Arici, MD Tara I. Chang, MD, MS Jennifer E. Flythe, MD, MPH Masafumi Fukagawa, MD, PhD Morgan E. Grams, MD, MPH, PhD Fan Fan Hou, MD, PhD Meg Jardine, MBBS, PhD Markus Ketteler, MD, FERA Magdalena Madero, MD Jolanta Ma yszko, MD, PhD Ikechi G. Okpechi, MBBS, FWACP, PhD Rukshana Shroff, MD, FRCPCH, PhD Laura Sol , MD Paul E. Stevens, MB, FRCP Sydney C.W. Tang, MD, PhD, FRCP, FACP, FHKCP, FHKAM Marcello A. Tonelli, MD, SM, MSc, FRCPC Christina M. Wyatt, MD KDIGO Staff John Davis, Chief Executive Of cer Danielle Green, Executive Director Michael Cheung, Chief Scienti c Of cer Melissa Thompson, Chief Operating Of cer Amy Earley, Guideline Development Director Kathleen Conn, Director of Communications Tanya Green, Events Director Coral Cyzewski, Events Coordinator www.kidney-international.org KDIGO executive committee Reference keys NOMENCLATURE AND DESCRIPTION FOR RATING GUIDELINE RECOMMENDATIONS Within each recommendation, the strength of recommendation is indicated as Level 1 or Level 2, and the quality of the supporting evidence is shown as A, B, C, or D. Grade Implications Patients Clinicians Policy Level 1 Strong We recommend Most people in your situation would want the recommended course of action, and only a small proportion would not. Most patients should receive the recommended course of action. The recommendation can be evaluated as a candidate for developing a policy or a performance measure. Level 2 Weak We suggest The majority of people in your situation would want the recommended course of action, but many would not. Different choices will be appropriate for different patients. 